Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
---|---|---|---|---|---|---|---|---|
![]() |
![]() |
![]() |
||||||
GSE227024 |
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1 [ChIP-Seq]
|
6 |
|
Xiaoping Su | Jun 14, 2023 | |||
GSE227025 |
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
|
10 |
|
Xiaoping Su | Jun 14, 2023 | |||
GSE228323 |
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. [ChIP-Seq]
|
4 | Xiaoping Su | Apr 19, 2023 | ||||
GSE228326 |
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
|
38 |
|
Xiaoping Su | Apr 19, 2023 | |||
GSE247093 |
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression [ChIP-Seq]
|
12 | Xiaoping Su | May 06, 2024 | ||||
GSE247095 |
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
|
28 |
|
Xiaoping Su | May 06, 2024 | |||
GSE252739 |
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). [ChIP-Seq]
|
2 | Xiaoping Su | Feb 01, 2024 | ||||
GSE252746 |
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
|
35 |
|
Xiaoping Su | Feb 01, 2024 | |||
GSE252935 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (ChIP-Seq)
|
12 |
|
Xiaoping Su | Mar 01, 2024 | |||
GSE252938 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor
|
34 | Xiaoping Su | Mar 01, 2024 |